3-(Fur-2-yl)-10-(2-phenylethyl)-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)- one, a novel adenosine receptor antagonist with A2A-mediated neuroprotective effects

ACS Chemical Neuroscience

Volumn 2, Issue 9, 2011, Pages 526-535

  Scatena, Alessia ^a   Fornai, Francesco ^a,b   Trincavelli, Maria Letizia ^a   Taliani, Sabrina ^a   Daniele, Simona ^c   Pugliesi, Isabella ^a   Cosconati, Sandro ^d   Martini, Claudia ^a   Da Settimo, Federico ^a  

^a UNIVERSITY OF PISA   (Italy)

^b IRCCS NEUROMED   (Italy)

^c ISTITUTO ITALIANO DI TECNOLOGIA   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

A2AAR antagonists; Cell viability; Human neuroblastoma cells; Neuroprotection; Neurotoxins; PC12 cells

Indexed keywords

(3 ( FUR 2 YL) 10 ( 2 PHENYLETHYL) [1,2,4]TRIAZINOL[4,3 A]BENZIMIDAZOL 4(10H) ONE); 1 METHYL 4 PHENYLPYRIDINIUM; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; ADENOSINE 5' (N ETHYLCARBOXAMIDE); ADENOSINE A2A RECEPTOR ANTAGONIST; METHAMPHETAMINE; NEUROPROTECTIVE AGENT; TRYPAN BLUE; UNCLASSIFIED DRUG; 3 (FUR 2 YL) 10 (2 PHENYLETHYL) (1,2,4)TRIAZINO(4,3 A)BENZIMIDAZOL 4(10H) ONE; 3-(FUR-2-YL)-10-(2-PHENYLETHYL)-(1,2,4)TRIAZINO(4,3-A)BENZIMIDAZOL-4(10H)-ONE; 4 AMINOBUTYRIC ACID A RECEPTOR; ADENOSINE A1 RECEPTOR; ADENOSINE A2 RECEPTOR ANTAGONIST; ADENOSINE A2A RECEPTOR; BENZIMIDAZOLE DERIVATIVE; CYCLIC AMP; DOPAMINE 2 RECEPTOR; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTOXIN; TRIAZINE DERIVATIVE;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOLOGY; CYTOTOXICITY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; MOLECULAR LIBRARY; NEUROBLASTOMA CELL LINE; NEUROPROTECTION; NEUROTOXICITY; PC12 CELL LINE; ANIMAL; CELL DEATH; CELL SURVIVAL; CHO CELL; COMPUTER SIMULATION; DRUG ANTAGONISM; DRUG EFFECT; HAMSTER; MEMBRANE; METABOLISM; PC12 CELL; RAT; SYNTHESIS;

1-METHYL-4-PHENYLPYRIDINIUM; ADENOSINE A2 RECEPTOR ANTAGONISTS; ANIMALS; BENZIMIDAZOLES; CELL DEATH; CELL SURVIVAL; CHO CELLS; COMPUTER SIMULATION; CRICETINAE; CYCLIC AMP; HUMANS; INDICATORS AND REAGENTS; MEMBRANES; METHAMPHETAMINE; NEUROPROTECTIVE AGENTS; NEUROTOXINS; PC12 CELLS; RATS; RECEPTOR, ADENOSINE A1; RECEPTOR, ADENOSINE A2A; RECEPTORS, DOPAMINE D2; RECEPTORS, GABA-A; RECEPTORS, N-METHYL-D-ASPARTATE; TRIAZINES;

EID: 84876034737     PISSN: None     EISSN: 19487193     Source Type: Journal    
DOI: 10.1021/cn200036s     Document Type: Article

References (56)

1. Poulsen, S. A., and Quinn, R. J. (1998) Adenosine receptors: new opportunities for future drugs. Bioorg. Med. Chem. 6, 619-641.
2. Fredholm, B. B., Arslan, G., Halldner, L., Kull, B., Schulte, G., and Wasserman, W. (2000) Structure and function of adenosine receptors and their genes. Naunyn-Schmiedeberg's Arch. Pharmacol. 362, 364-374.
3. Fredholm, B. B., IJzerman, A. P., Jacobson, K. A., Klotz, K.-N., and Linden, J. (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol. Rev. 53, 527-552.
4. Schulte, G., and Fredholm, B. B. (2000) Human adenosine A(1), A(2A), A(2B), and A(3) receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2. Mol. Pharmacol. 58, 477-482.
5. Jacobson, K. A., and Gao, Z. G. (2006) Adenosine receptors as therapeutic targets. Nat. Rev. Drug Discovery 5, 247-264.
6. Moro, S., Gao, Z. G., Jacobson, K. A., and Spalluto, G. (2006) Progress in the pursuit of therapeutic adenosine receptor antagonists. Med. Res. Rev. 26, 131-159.
7. Ribeiro, J. A., Sebastiao, A. M., and de Mendonca, A. (2002) Adenosine receptors in the nervous system: pathophysiological implications. Prog. Neurobiol. 68, 377-392.
8. Muller, C. E. (1997) A1-adenosine receptor antagonists. Expert Opin. Ther. Pat. 7, 419-440.
9. Muller, C. E. (2000) A2A-adenosine receptor antagonists-future drugs for Parkinson's disease?. Drugs Future 25, 1043-1052.
10. Baraldi, P. G., Tabrizi, M. A., Gessi, S., and Borea, P. A. (2008) Adenosine receptor antagonists: translating medicinal chemistry and pharmacology into clinical utility. Chem. Rev. 108, 238-263.
11. Press, N. J., Gessi, S., Borea, P. A., and Polosa, R. (2007) Therapeutic potential of adenosine receptor antagonists and agonists. Expert Opin. Ther. Pat. 17, 979-991.
12. Morelli, M., Carta, A. R., and Jenner, P. (2009) Adenosine A2A receptors and Parkinson's disease. Handb. Exp. Pharmacol. 193, 589-615.
13. Popoli, P., Blum, D., Domenici, M. R., Burnouf, S., and Chern, Y. (2008) A critical evaluation of adenosine A2A receptors as potentially "druggable" targets in Huntington's disease. Curr. Pharm. Des. 14, 1500-1511.
14. Trevitt, J., Vallance, C., Harris, A., and Goode, T. (2009) Adenosine antagonists reverse the cataleptic effects of haloperidol: implications for the treatment of Parkinson's disease. Pharmacol., Biochem. Behav. 92, 521-527.
15. Gao, Y., and Phillis, J. W. (1994) CGS 15943, an adenosine receptor antagonist, reduces cerebral ischemic injury in the Mongolian gerbil. Life Sci. 55, 61-65.
16. Monopoli, A. L. G., Forlani, A., Mattavelli, A., and Ongini, E. (1998) Blockade of adenosine A2A receptors by SCH 58261 results in neuroprotective effects in cerebral ischemia in rats. Neuro Report 9, 3955-3959.
17. Chen, J. F., Huang, Z., Ma, J., Zhu, J., Moratalla, R., Standaert, D., Moskowitz, M. A., Fink, J. S., and Schwarzschild, M. A. (1999) A(2A) adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J. Neurosci. 19, 9192-9200.
18. Chen, J. F., Sonsalla, P. K., Pedata, F., Melani, A., Domenici, M. R., Popoli, P., Geiger, J., Lopes, L. V., and de Mendonca, A. (2007) Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation. Prog. Neurobiol. 83, 310-331.
19. Cuhna, R. A. (2005) Neuroprotection by adenosine in the brain: from A1 receptor activation to A2A receptor blockade. Purinergic Signalling 1, 111-134.
20. Pintor, A., Galluzzo, M., Grieco, R., Pezzola, A., Reggio, R., and Popoli, P. (2004) Adenosine A2A receptor antagonists prevent the increase in striatal glutamate levels induced by glutamate uptake inhibitors. J. Neurochem. 89, 152-6.
21. Popoli, P., Betto, P., Reggio, R., and Ricciarello, G. (1995) Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur. J. Pharmacol. 287, 215-217.
22. Stone, T.W., Ceruti, S., and Abbracchio, M. P. (2009) Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Handb. Exp. Pharmacol. 193, 535-587.
23. Mally, J., and Stone, T. W. (1994) The effect of theophylline on parkinsonian symptoms. J. Pharm. Pharmacol. 46, 515-517.
24. Mally, J., and Stone, T. W. (1996) Potential role of adenosine antagonist therapy in pathological tremor disorders. Pharmacol. Ther. 72, 243-250.
25. Mally, J., and Stone, T. W. (1998) Potential role of adenosine A2A receptor antagonists in the treatment of movement disorders. CNS Drugs 10, 311-320.
26. Kanda, T., Jackson, M. J., Smith, L. A., Pearce, R. K., Nakamura, J., Kase, H., Kuwana, Y., and Jenner, P. (1998) Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann. Neurol. 43, 507-513.
27. Grondin, R., Bedard, P. J., Hadj Tahar, A., Gregoire, L., Mori, A., and Kase, H. (1999) Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treatedmonkeys. Neurol. 52, 1673-1677.
28. Ikeda, K., Kurokawa, M., Aoyama, S., and Kuwana, Y. (2002) Neuroprotection by adenosine A2A receptor blockade in experimental models of Parkinson's disease. J. Neurochem. 80, 262-270.
29. Nicklas, W. J., Vyas, I., and Heikkila, R. E. (1985) Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. Life Sci. 36, 2503-2538.
30. Ramsay, R. R., Salach, J. I., and Singer, T. P. (1986) Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. Biochem. Biophys. Res. Commun. 134, 743-748.
31. Da Settimo, F., Primofiore, G., Taliani, S., Marini, A. M., La Motta, C., Novellino, E., Greco, G., Lavecchia, A., Trincavelli, L., and Martini, C. (2001) 3-Aryl[1,2,4]triazino[4,3-α]benzimidazol-4(10H)- ones: a new class of selective A1 adenosine receptor antagonists. J. Med. Chem. 44, 316-327.
32. Da Settimo, F., Primofiore, G., Taliani, S., LaMotta, C., Novellino, E., Greco, G., Lavecchia, A., Cosimelli, B., Iadanza, M., Klotz, K.-N., Tuscano, D., Trincavelli, M. L., and Martini, C. (2004) A1 adenosine receptor antagonists, 3-aryl[1,2,4]triazino[4,3-α]benzimidazol-4-(10H)- ones (ATBIs) and N-alkyl and N-acyl-(7-substituted-2-phenylimidazo- [1,2-α][1,3,5]triazin-4-yl)amines (ITAs): Different recognition of bovine and human binding sites. Drug Dev. Res. 63, 1-7.
33. Novellino, E., Abignente, E., Cosimelli, B., Greco, G., Iadanza, M., Laneri, S., Lavecchia, A., Rimoli, M. G., Da Settimo, F., Primofiore, G., Tuscano, D., Trincavelli, L., and Martini, C. (2002) Design, synthesis and biological evaluation of novel N-alkyl- and N-acyl-(7-substituted-2-phenylimidazo[1,2-α][1,3,5]triazin-4-yl)amines (ITAs) as novel A(1) adenosine receptor antagonists. J. Med. Chem. 45, 5030-5036.
34. Novellino, E., Cosimelli, B., Ehlardo, M., Greco, G., Iadanza, M., Lavecchia, A., Rimoli, M. G., Sala, A., Da Settimo, A., Primofiore, G., Da Settimo, F., Taliani, S., LaMotta, C., Klotz, K.-N., Tuscano, D., Trincavelli, M. L., and Martini, C. (2005) 2-(Benzimidazol-2-yl)quinoxalines: a novel class of selective antagonists at human A(1) and A(3) adenosine receptors designed by 3D database searching. J. Med. Chem. 48, 8253-8260.
35. Da Settimo, F., Primofiore, G., Taliani, S., Marini, A. M., La Motta, C., Simorini, F., Salerno, S., Sergianni, V., Tuccinardi, T., Martinelli, A., Cosimelli, B., Greco, G., Novellino, E., Ciampi, O., Trincavelli, M. L., and Martini, C. (2007) 5-amino-2-phenyl[1,2,3]- triazolo[1,2-α][1,2,4]benzotriazin-1-one: a versatile scaffold to obtain potent and selective A3 adenosine receptor antagonists. J. Med. Chem. 50, 5676-5684.
36. Cosimelli, B., Greco, G., Ehlardo, M., Novellino, E., Da Settimo, F., Taliani, S., La Motta, C., Bellandi, M., Tuccinardi, T., Martinelli, A., Ciampi, O., Trincavelli, M. L., and Martini, C. (2008) Derivatives of 4-amino-6-hydroxy-2-mercaptopyrimidine as novel, potent, and selective A3 adenosine receptor antagonists. J. Med. Chem. 51, 1764-1770.
37. Taliani, S., La Motta, C., Mugnaini, L., Simorini, F., Salerno, S., Marini, A. M., Da Settimo, F., Cosconati, S., Cosimelli, B., Greco, G., Limongelli, V., Marinelli, L., Novellino, E., Ciampi, O., Daniele, S., Trincavelli, M. L., and Martini, C. (2010) Novel N2-substituted pyrazolo- [3,4-d]pyrimidine adenosine A3 receptor antagonists: inhibition of A3-mediated human glioblastoma cell proliferation. J. Med. Chem. 53, 3954-3963.
38. Parihar, H. S., Suryanarayanan, A., Ma, C., Joshi, P., Venkataraman, P., Schulte, M. K., and Kirschbaum, K. S. (2001) 5-HT(3)R binding of lerisetron: an interdisciplinary approach to drug-receptor interactions. Bioorg. Med. Chem. Lett. 11, 2133-2136.
39. Primofiore, G., Da Settimo, F., Taliani, S., Marini, A. M., La Motta, C., Novellino, E., Greco, G., Gesi, M., Trincavelli, L., and Martini, C. (2000) 3-Aryl-[1,2,4]triazino[4,3-α]benzimidazol-4(10H)-ones: tricyclic heteroaromatic derivatives as a new class of benzodiazepine receptor ligands. J. Med. Chem. 43, 96-102.
40. Poucher, S. M., Keddie, J. R., Singh, P., Stoggall, S. M., Caulkett, P. W., Jones, G., and Coll, M. G. (1995) The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist. Br. J. Pharmacol. 115, 1096-1102.
41. Nordstedt, C., and Fredholm, B. B. (1990) A modification of a protein-binding method for rapid quantification of cAMP in cell-culture supernatants and body fluid. Anal. Biochem. 189, 231-234.
42. Fornai, F., Lenzi, P., Lazzeri, G., Ferrucci, M., Fulceri, F., Giorgi, F. S., Falleni, A., Ruggieri, S., and Paparelli, A. (2007) Fine ultrastructure and biochemistry of PC12 cells: a comparative approach to understand neurotoxicity. Brain Res. 1129, 174-190.
43. Seiden, L. S. (1985) Methamphetamine: toxicity to dopaminergic neurons. NIDA Res. Monogr. 62, 100-116.
44. Fornai, F., Lenzi, P., Gesi, M., Soldani, P., Ferrucci, M., Lazzeri, G., Capobianco, L., Battaglia, G., De Blasi, A., Nicoletti, F., and Paparelli, A. (2004) Methamphetamine produces neuronal inclusions in the nigrostriatal system and in PC12 cells. J. Neurochem. 88, 114-123.
45. Gluck, M. R., Moy, L. Y., Jayatilleke, E., Hogan, K. A., Manzino, L., and Sonsalla, P. K. (2001) Parallel increases in lipid and protein oxidative markers in several mouse brain regions after methamphetamine treatment. J. Neurochem. 79, 152-160.
46. Fornai, F., Lenzi, P., Ferrucci, M., Lazzeri, G., di Poggio, A. B., Natale, G., Busceti, C. L., Biagioni, F., Giusiani, M., Ruggieri, S., and Paparelli, A. (2005) Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice. Brain Res. Bull. 65, 405-413.
47. Iacovelli, L., Fulceri, F., De Blasi, A., Nicoletti, F., Ruggieri, S., and Fornai, F. (2006) The neurotoxicity of amphetamines: bridging drugs of abuse and neurodegenerative disorders. Exp. Neurol. 201, 24-31.
48. Ferrucci, M., Pasquali, L., Paparelli, A., Ruggieri, S., and Fornai, F. (2008) Pathways of methamphetamine toxicity. Ann. N.Y. Acad. Sci. 1139, 177-185.
49. Ferrucci, M., Pasquali, L., Ruggieri, S., Paparelli, A., and Fornai, F. (2008) Alpha-synuclein and autophagy as common steps in neurodegeneration. Parkinsonism Relat. Disord. 14 (Suppl 2), S180-184.
50. Seiden, L. S., Sabol, K. E., and Ricaurte, G. A. (1993) Amphetamine: effects on catecholamine systems and behavior. Annu. Rev. Pharmacol. Toxicol. 33, 639-677.
51. Klotz, K.-N., Hessling, J., Hegler, J., Owman, C., Kull, B., Fredholm, B. B., and Lohse, M. J. (1998) Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 357, 1-9.
52. Costanzo, A, Guerrini, G, Ciciani, G, Bruni, F, Selleri, S, Costa, B, Martini, C, Lucacchini, A, Aiello, P.M., and Ipponi, A. (1999) Benzodiazepine receptor ligands. 4. Synthesis and pharmacological evaluation of 3-heteroaryl-8-chloropyrazolo[5,1-c][1,2,4] benzotriazine 5-oxides. J. Med. Chem. 42 (12), 2218-2226.
53. Trincavelli, M. L., Cuboni, S, Catena Dell'osso, M, Maggio, R, Klotz, K. N., Novi, F, Panighini, A, Daniele, S, and Martini, C. (2010) Receptor crosstalk: haloperidol treatment enhances A(2A) adenosine receptor functioning in a transfected cell model. Purinergic Signalling 6 (4), 373-381.
54. Marvizón, J. C., Lewin, A. H., and Skolnick, P. (1989) 1-Aminocyclopropane carboxylic acid: a potent and selective ligand for the glycine modulatory site of the N-methyl-D-aspartate receptor complex. J. Neurochem. 52 (3), 992-994.
55. Cheng, Y., and Prusoff, W. H. (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108.
56. Papanicolau, G. N. (1942) A new procedure for staining vaginal smears. Science 95, 438-439.